Effect of low-dose naloxone infusion on fentanyl requirements in critically ill children

Pediatrics

Volumn 121, Issue 5, 2008, Pages

  Darnell, Cindy Maria ^a,c   Thompson, Jennifer ^b   Stromberg, Daniel ^a   Roy, Lonnie ^c   Sheeran, Paul ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b Naval Medical Center   (United States)

^c CHILDREN S MEDICAL CENTER   (United States)

Author keywords

Controlled trial; Critically ill children; Opiate dependent neonate; Pain management; Randomized; Sedation

Indexed keywords

FENTANYL; MIDAZOLAM; NALOXONE; PLACEBO; HYPNOTIC SEDATIVE AGENT; NARCOTIC ANALGESIC AGENT; NARCOTIC ANTAGONIST;

ANALGESIA; ANAMNESIS; ARTICLE; ARTIFICIAL VENTILATION; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DOUBLE BLIND PROCEDURE; DRUG DEPENDENCE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG WITHDRAWAL; FEMALE; HUMAN; INTENSIVE CARE; KIDNEY DISEASE; LIVER DISEASE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NEUROLOGIC DISEASE; PEDIATRICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; ADOLESCENT; CONSCIOUS SEDATION; CRITICAL ILLNESS; INFANT; INTRAVENOUS DRUG ADMINISTRATION; NEWBORN; PRESCHOOL CHILD; WITHDRAWAL SYNDROME;

ADOLESCENT; ANALGESICS, OPIOID; CHILD; CHILD, PRESCHOOL; CONSCIOUS SEDATION; CRITICAL ILLNESS; DOUBLE-BLIND METHOD; FEMALE; FENTANYL; HUMANS; HYPNOTICS AND SEDATIVES; INFANT; INFANT, NEWBORN; INFUSIONS, INTRAVENOUS; INTENSIVE CARE UNITS, PEDIATRIC; MALE; MIDAZOLAM; NALOXONE; NARCOTIC ANTAGONISTS; RESPIRATION, ARTIFICIAL; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 44449168790     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2007-1468     Document Type: Article

References (58)

1. McArdle P. Intravenous analgesia. Crit Care Clin. 1999;15(1): 89-104
2. Golianu B, Krane EJ, Galloway KS, Yaster M. Pediatric acute pain management. Pediatr Clin North Am. 2000;47(3):559-587
3. Anand KJ, Arnold JH. Opioid tolerance and dependence in infants and children. Crit Care Med. 1994;22(2):334-342
4. Tobias JD. Tolerance, withdrawal, and physical dependency after long-term sedation and analgesia of children in the pediatric intensive care unit. Crit Care Med. 2000;28(6):2122-2132
5. Arnold JH, Truog RD, Orav EJ, Scavone JM, Hershenson MB. Tolerance and dependence in neonates sedated with fentanyl during extracorporeal membrane oxygenation. Anesthesiology. 1990;73(6):1136-1140
6. Waldhoer M, Bartlett SE, Whistler JL. Opioid receptors. Annu Rev Biochem. 2004;73:953-990
7. Kieffer BL, Evans CJ. Opioid tolerance-in search of the holy grail. Cell. 2002;108(5):587-590
8. Suresh S, Anand KJ. Opioid tolerance in neonates: a state-of-the-art review. Paediatr Anaesth. 2001;11(5):511-521
9. Ueda H, Inoue M, Mizuno K. New approaches to study the development of morphine tolerance and dependence. Life Sci. 2003;74(2-3):313-320
10. Raith K, Hochhaus G. Drugs used in the treatment of opioid tolerance and physical dependence: a review. Int J Clin Pharmacol Ther. 2004;42(4):191-203
11. Crain SM, Shen KF. Modulatory effects of Gs-coupled excitatory opioid receptor functions on opioid analgesia, tolerance, and dependence. Neurochem Res. 1996;21(11):1347-1351
12. Avidor-Reiss T, Nevo I, Levy R, Pfeuffer T, Vogel Z. Chronic opioid treatment induces adenylyl cyclase V superactivation. Involvement of Gbetagamma. J Biol Chem. 1996;271(35): 21309-21315
13. Nevo I, Avidor-Reiss T, Levy R, Bayewitch M, Heldman E, Vogel Z. Regulation of adenylyl cyclase isozymes on acute and chronic activation of inhibitory receptors. Mol Pharmacol. 1998;54(2):419-426
14. Nestler EJ, Hope BT, Widnell KL. Drug addiction: a model for the molecular basis of neural plasticity. Neuron. 1993;11(6):995-1006
15. Avidor-Reiss T, Bayewitch M, Levy R, Matus-Leibovitch N, Nevo I, Vogel Z. Adenylylcyclase supersensitization in mu-opioid receptor-transfected Chinese hamster ovary cells following chronic opioid treatment. J Biol Chem. 1995;270(50): 29732-29738
16. Sharma SK, Klee WA, Nirenberg M. Dual regulation of ade-nylate cyclase accounts for narcotic dependence and tolerance.Proc Natl Acad Sci USA. 1975;72(8):3092-3096
17. Crain SM, Shen KF. Antagonists of excitatory opioid receptor functions enhance morphine's analgesic potency and attenuate opioid tolerance/dependence liability. Pain. 2000;84(2-3): 121-131
18. Shen KF, Crain SM. Dual opioid modulation of the action potential duration of mouse dorsal root ganglion neurons in culture. Brain Res. 1989;491(2):227-242
19. Crain SM, Shen KF. Modulation of opioid analgesia, tolerance and dependence by Gs-coupled, GM1 ganglioside-regulated opioid receptor functions. Trends Pharmacol Sci. 1998;19(9): 358-365
20. Woolf CJ. Analgesia and hyperalgesia produced in the rat by intrathecal naloxone. Brain Res. 1980;189(2):593-597
21. Crain SM, Shen KF. Ultra-low concentrations of naloxone selectively antagonize excitatory effects of morphine on sensory neurons, thereby increasing its antinociceptive potency and attenuating tolerance/dependence during chronic cotreat-ment. Proc Natl Acad Sci USA. 1995;92(23):10540-10544
22. Shen KF, Crain SM. Ultra-low doses of naltrexone or etorphine increase morphine's antinociceptive potency and attenuate tolerance/dependence in mice. Brain Res. 1997;757(2): 176-190
23. Crain SM, Shen KF, Chalazonitis A. Opioids excite rather than inhibit sensory neurons after chronic opioid exposure of spinal cord-ganglion cultures. Brain Res. 1988;455(1):99-109
24. Crain SM, Shen KF. Opioids can evoke direct receptor-mediated excitatory as well as inhibitory effects on sensory neuron action potentials. NIDA Res Monogr. 1990;105:34-39
25. Joshi GP, Duffy L, Chehade J, Wesevich J, Gajraj N, Johnson ER. Effects of prophylactic nalmefene on the incidence of morphine-related side effects in patients receiving intravenous patient-controlled analgesia. Anesthesiology. 1999;90(4): 1007-1011
26. Gan TJ, Ginsberg B, Glass PS, Fortney J, Jhaveri R, Perno R. Opioid-sparing effects of a low-dose infusion of naloxone in patient-administered morphine sulfate. Anesthesiology. 1997; 87(5):1075-1081
27. Levine JD, Gordon NC, Taiwo YO, Coderre TJ. Potentiation of pentazocine analgesia by low-dose naloxone. J Clin Invest. 1988;82(5):1574-1577
28. Cheung CL, van Dijk M, Green JW, Tibboel D, Anand KJ. Effects of low-dose naloxone on opioid therapy in pediatric patients: a retrospective case-control study. Intensive Care Med. 2007;33(1):190-
29. Katz R, Kelly HW, Hsi A. Prospective study on the occurrence of withdrawal in critically ill children who receive fentanyl by continuous infusion. Crit Care Med. 1994;22(5):763-767
30. Murray L. Physicians' Desk Reference 2005. 59th ed. Montvale, NJ: Thomson PDR; 2005
31. Devlin JW, Boleski G, Mlynarek M, et al. Motor Activity Assessment Scale: a valid and reliable sedation scale for use with mechanically ventilated patients in an adult surgical intensive care unit. Crit Care Med. 1999;27(7):1271-1275
32. Curley MA, Hibberd PL, Fineman LD, et al. Effect of prone positioning on clinical outcomes in children with acute lung injury: a randomized controlled trial. JAMA. 2005;294(2): 229-237
33. Clemmer TP, Wallace JC, Spuhler VJ, Bailey PP, Devlin JW. Origins of the Motor Activity Assessment Scale score: a multi-institutional process. Crit Care Med. 2000;28(8):3124
34. Curley MA, Harris SK, Fraser KA, Johnson RA, Arnold JH. State Behavioral Scale: a sedation assessment instrument for infants and young children supported on mechanical ventilation. Pediatr Crit Care Med. 2006;7(2):107-114
35. Manworren RC, Hynan LS. Clinical validation of FLACC: pre-verbal patient pain scale. Pediatr Nurs. 2003;29(2):140-146
36. Voepel-Lewis T, Merkel S, Tait AR, Trzcinka A, Malviya S. The reliability and validity of the Face, Legs, Activity, Cry, Con-solability observational tool as a measure of pain in children with cognitive impairment. Anesth Analg. 2002;95(5): 1224-1229
37. Finnegan LP, Connaughton JF Jr, Kron RE, Emich JP. Neonatal abstinence syndrome: assessment and management. Addict Dis. 1975;2(1-2):141-158
38. Leteurtre S, Martinot A, Duhamel A, Proulx F, Grandbastien B, Cotting J, et al. Validation of the paediatric logistic organ dysfunction (PELOD) score: prospective, observational, multi-centre study. Lancet. 2003;362(9379):192-197
39. Cepeda MS, Africano JM, Manrique AM, Fragoso W, Carr DB. The combination of low dose of naloxone and morphine in PCA does not decrease opioid requirements in the postoperative period. Pain. 2002;96(1-2):73-79
40. Facts & Comparisons 4.0: Administration and dosage. Available at: http://online.factsandcomparisons.com/printsection.aspx?id=662859§ion= admin-dosage. Accessed March 17, 2008
41. Kendrick WD, Woods AM, Daly MY, Birch RF, DiFazio C. Naloxone versus nalbuphine infusion for prophylaxis of epi-dural morphine-induced pruritus. Anesth Analg. 1996;82(3):641-647
42. Rolly G, Poelaert J, Mungroop H, Paelinck H. A combination of buprenorphine and naloxone compared with buprenorphine administered intramuscularly in postoperative patients. J Int Med Res. 1986;14(3):148-152
43. Stoller KB, Bigelow GE, Walsh SL, Strain EC. Effects of buprenorphine/naloxone in opioid-dependent humans. Psy-chopharmacology (Berl). 2001;154(3):230-242
44. Rawal N, Schott U, Dahlstrom B, et al. Influence of naloxone infusion on analgesia and respiratory depression following epi-dural morphine. Anesthesiology. 1986;64(2):194-1201
45. Mehlisch DR. The combination of low dose of naloxone and morphine in patient-controlled (PCA) does not decrease opioid requirements in the postoperative period. Pain. 2003;101(1-2): 209-211, author reply 211-212
46. Tobias JD. Sedation and analgesia in the pediatric intensive care unit. Pediatr Ann. 2005;34(8):636-645
47. Berde CB, Sethna NF. Analgesics for the treatment of pain in children. N Engl J Med. 2002;347(14):1094-1103
48. Kress JP, Hall JB. Sedation in the mechanically ventilated patient. Crit Care Med. 2006;34(10):2541-2546
49. Ummenhofer WC, Arends RH, Shen DD, Bernards CM. Comparative spinal distribution and clearance kinetics of intrathecally administered morphine, fentanyl, alfentanil, and sufentanil. An-esthesiology. 2000;92(3):739-753
50. Narita M, Imai S, Itou Y, Yajima Y, Suzuki T. Possible involvement of mu1-opioid receptors in the fentanyl-or morphine-induced antinociception at supraspinal and spinal sites. Life Sci. 2002;70(20):2341-2354
51. Clark MJ, Furman CA, Gilson TD, Traynor JR. Comparison of the relative efficacy and potency of mu-opioid agonists to activate Galpha(i/o) proteins containing a pertussis toxin-insensitive mutation. J Pharmacol Exp Ther. 2006;317(2): 858-864
52. Saidak Z, Blake-Palmer K, Hay DL, Northup JK, Glass M.Differential activation of G-proteins by mu-opioid receptor agonists. Br J Pharmacol. 2006;147(6):671-680
53. th ed. New York, NY: The McGraw-Hill Companies, Inc;1996:521-556
54. Haeseler G, Foadi N, Ahrens J, Dengler R, Hecker H, Leuwer M. Tramadol, fentanyl and sufentanil but not morphine block voltage-operated sodium channels. Pain. 2006;126(1-3): 234-244
55. Cepeda MS, Alvarez H, Morales O, Carr DB. Addition of ul-tralow dose naloxone to postoperative morphine PCA: unchanged analgesia and opioid requirement but decreased incidence of opioid side effects. Pain. 2004;107(1-2):41-46
56. Playfor S, Jenkins I, Boyles C, et al. Consensus guidelines on sedation and analgesia in critically ill children. Intensive Care Med. 2006;32(8):1125-1136
57. Prins S, van Dijk M, Tibboel D. Sedation and analgesia in the PICU: many questions remain. Intensive Care Med.2006;32(8): 1103-1105
58. Takahashi M, Sugiyama K, Hori M, Chiba S, Kusaka K. Naloxone reversal of opioid anesthesia revisited: clinical evaluation and plasma concentration analysis of continuous nalox-one infusion after anesthesia with high-dose fentanyl. JAnesth. 2004;18(1):1-8